Literature DB >> 23656504

In vitro evidence of the presence of mesenchymal stromal cells in cervical cancer and their role in protecting cancer cells from cytotoxic T cell activity.

Juan J Montesinos1, María de L Mora-García, Héctor Mayani, Eugenia Flores-Figueroa, Rosario García-Rocha, Guadalupe R Fajardo-Orduña, Marta E Castro-Manrreza, Benny Weiss-Steider, Alberto Monroy-García.   

Abstract

Mesenchymal stromal cells (MSCs) have been isolated from different tumors and it has been suggested that they support tumor growth through immunosuppression processes that favor tumor cell evasion from the immune system. To date, however, the presence of MSCs in cervical cancer (CeCa) and their possible role in tumor growth remains unknown. Herein we report on the presence of MSCs in cervical tissue, both in normal conditions (NCx-MSCs) and in CeCa (CeCa-MSCs), and described several biological properties of such cells. Our study showed similar patterns of cell surface antigen expression, but distinct differentiation potentials, when we compared both cervical MSC populations to MSCs from normal bone marrow (BM-MSCs, the gold standard). Interestingly, CeCa-MSCs were negative for the presence of human papilloma virus, indicating that these cells are not infected by such a viral agent. Also, interestingly, and in contrast to NCx-MSCs, CeCa-MSCs induced significant downregulation of surface HLA class I molecules (HLA-A*0201) on CaSki cells and other CeCa cell lines. We further observed that CeCa-MSCs inhibited antigen-specific T cell recognition of CaSki cells by cytotoxic T lymphocytes (CTLs). HLA class I downregulation on CeCa cells correlated with the production of IL-10 in cell cocultures. Importantly, this cytokine strongly suppressed recognition of CeCa cells by CTLs. In summary, this study demonstrates the presence of MSCs in CeCa and suggests that tumor-derived MSCs may provide immune protection to tumor cells by inducing downregulation of HLA class I molecules. This mechanism may have important implications in tumor growth.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23656504      PMCID: PMC3761677          DOI: 10.1089/scd.2013.0084

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  52 in total

1.  Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells.

Authors:  Ida Rasmusson; Olle Ringdén; Berit Sundberg; Katarina Le Blanc
Journal:  Transplantation       Date:  2003-10-27       Impact factor: 4.939

2.  Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro.

Authors:  H Karlsson; T Erkers; S Nava; S Ruhm; M Westgren; O Ringdén
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

3.  Human mesenchymal stromal cells from adult and neonatal sources: comparative analysis of their morphology, immunophenotype, differentiation patterns and neural protein expression.

Authors:  J J Montesinos; E Flores-Figueroa; S Castillo-Medina; P Flores-Guzmán; E Hernández-Estévez; G Fajardo-Orduña; S Orozco; H Mayani
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

Review 4.  The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible "hard" lesions.

Authors:  Federico Garrido; Ignacio Algarra; Angel M García-Lora
Journal:  Cancer Immunol Immunother       Date:  2010-07-13       Impact factor: 6.968

5.  Human leukocyte antigen-G (HLA-G) expression in cervical lesions: association with cancer progression, HPV 16/18 infection, and host immune response.

Authors:  Dan-dan Dong; Hong Yang; Ke Li; Gang Xu; Lin-hong Song; Xiao-li Fan; Xin-lian Jiang; Shang-mian Yie
Journal:  Reprod Sci       Date:  2010-05-05       Impact factor: 3.060

6.  Clinicopathological significance of stromal myofibroblasts in invasive ductal carcinoma of the breast.

Authors:  Cui Yazhou; Shen Wenlv; Zhang Weidong; Wu Licun
Journal:  Tumour Biol       Date:  2004 Sep-Dec

7.  Heterogeneity among human bone marrow-derived mesenchymal stem cells and neural progenitor cells.

Authors:  Wichard Vogel; Frank Grünebach; Conrad A Messam; Lothar Kanz; Wolfram Brugger; Hans-Jörg Bühring
Journal:  Haematologica       Date:  2003-02       Impact factor: 9.941

8.  Expression of human leukocyte antigen-G and its correlation with interleukin-10 expression in cervical carcinoma.

Authors:  B S Yoon; Y T Kim; J W Kim; S H Kim; J H Kim; S W Kim
Journal:  Int J Gynaecol Obstet       Date:  2007-05-09       Impact factor: 3.561

9.  Interleukin-10 reduces natural killer sensitivity and downregulates MHC class I expression on H-ras-transformed cells.

Authors:  T Tsuruma; A Yagihashi; T Torigoe; N Sato; K Kikuchi; N Watanabe; K Hirata
Journal:  Cell Immunol       Date:  1998-03-15       Impact factor: 4.868

10.  Tumour-associated fibroblasts and mesenchymal stem cells: more similarities than differences.

Authors:  Virgil Paunescu; Florina M Bojin; Calin A Tatu; Oana I Gavriliuc; Adriana Rosca; Alexandra T Gruia; Gabriela Tanasie; Carmen Bunu; Daniela Crisnic; Mihaela Gherghiceanu; Fabian R Tatu; Carmen S Tatu; Simona Vermesan
Journal:  J Cell Mol Med       Date:  2011-03       Impact factor: 5.310

View more
  18 in total

Review 1.  Immunological hallmarks of stromal cells in the tumour microenvironment.

Authors:  Shannon J Turley; Viviana Cremasco; Jillian L Astarita
Journal:  Nat Rev Immunol       Date:  2015-10-16       Impact factor: 53.106

Review 2.  Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets.

Authors:  Yufang Shi; Liming Du; Liangyu Lin; Ying Wang
Journal:  Nat Rev Drug Discov       Date:  2016-11-04       Impact factor: 84.694

3.  Treg/Th17 polarization by distinct subsets of breast cancer cells is dictated by the interaction with mesenchymal stem cells.

Authors:  Shyam A Patel; Meneka A Dave; Sarah A Bliss; Agata B Giec-Ujda; Margarette Bryan; Lillian F Pliner; Pranela Rameshwar
Journal:  J Cancer Stem Cell Res       Date:  2014-05-29

4.  Differences in chemotaxis of human mesenchymal stem cells and cervical cancer cells.

Authors:  Yizuo Song; Ruyi Li; Miaomiao Ye; Chunyu Pan; Lihong Zheng; Zhi-Wei Wang; Xueqiong Zhu
Journal:  Apoptosis       Date:  2022-07-18       Impact factor: 5.561

5.  Local immunosuppression induced by high viral load of human papillomavirus: characterization of cellular phenotypes producing interleukin-10 in cervical neoplastic lesions.

Authors:  Thiago Theodoro Martins Prata; Camila Mareti Bonin; Alda Maria Teixeira Ferreira; Cacilda Tezelli Junqueira Padovani; Carlos Eurico dos Santos Fernandes; Ana Paula Machado; Inês Aparecida Tozetti
Journal:  Immunology       Date:  2015-07-01       Impact factor: 7.397

Review 6.  Multipotent Mesenchymal Stromal Cells: Possible Culprits in Solid Tumors?

Authors:  Pascal David Johann; Ingo Müller
Journal:  Stem Cells Int       Date:  2015-07-27       Impact factor: 5.443

Review 7.  Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications.

Authors:  Marta E Castro-Manrreza; Juan J Montesinos
Journal:  J Immunol Res       Date:  2015-04-19       Impact factor: 4.818

Review 8.  The roles of mesenchymal stem cells in tumor inflammatory microenvironment.

Authors:  Zhao Sun; Shihua Wang; Robert Chunhua Zhao
Journal:  J Hematol Oncol       Date:  2014-02-06       Impact factor: 17.388

9.  Potential therapeutic effect of the secretome from human uterine cervical stem cells against both cancer and stromal cells compared with adipose tissue stem cells.

Authors:  Noemí Eiró; Juan Sendon-Lago; Samuel Seoane; María A Bermúdez; Maria Luz Lamelas; Tomás Garcia-Caballero; José Schneider; Roman Perez-Fernandez; Francisco J Vizoso
Journal:  Oncotarget       Date:  2014-11-15

Review 10.  Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?

Authors:  Lisa Pleyer; Peter Valent; Richard Greil
Journal:  Int J Mol Sci       Date:  2016-06-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.